Epidemiology and antifungal susceptibility of Candida species isolated from hospitalized patients

Journal de Mycologie Medicale

Volumn 17, Issue 1, 2007, Pages 16-20

  Kalkanci, A ^a   Berk, E ^a   Aykan, B ^a   Caglar, K ^a   Hizel, K ^a   Arman, D ^a   Kustimur, S ^a  

^a GAZI UNIVERSITY   (Turkey)

Author keywords

Amphotericin B; Antifungal susceptibility testing; Candida; Caspofungin; Fluconazole; Nosocomial infection; Voriconazole

Indexed keywords

AMPHOTERICIN B; CASPOFUNGIN; FLUCONAZOLE; VORICONAZOLE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KEFYR; CANDIDA LUSITANIAE; CANDIDA NORVEGENSIS; CANDIDA PARAPSILOSIS; CANDIDA PELLICULOSA; CANDIDA TROPICALIS; FUNGUS ISOLATION; HOSPITAL INFECTION; HOSPITAL PATIENT; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN;

CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS;

EID: 33947109559     PISSN: 11565233     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mycmed.2006.11.003     Document Type: Article

References (20)

1. Arikan S., Sancak B., and Hascelik G. In vitro activity of caspofungin compared to amphotericin B, fluconazole, and itraconazole against Candida strains isolated in a Turkish university hospital. Med Mycol 43 (2005) 171-178
2. Bachmann S.P., Patterson T.F., and Lopez-Ribot J.L. In vitro activity of caspofungin (MK-0991) against Candida albicans clinical isolates displaying different mechanisms of azole resistance. J Clin Microbiol 40 (2002) 2228-2230
3. Cantón E., Pemán J., Viudes A., Quindós G., Gobernado M., and Espinel-Ingroff A. Minimum fungicidal concentrations of amphotericin B for bloodstream Candida species. Diagn Microbiol Infect Dis 45 (2003) 203-206
4. Chryssanthou E., and Cuenca-Estrella M. Comparison of the antifungal susceptibility testing subcommittee of the European Committee on antibiotic susceptibility testing proposed Standard and the E-test with the NCCLS broth microdilution methods for voriconazole and caspofungin susceptiblity testing of yeast species. J Clin Microbiol 40 (2002) 3841-3844
5. Cuenca-Estrella M., Rodriguez D., Almirante B., Morgan J., Planes A.M., Almela M., et al. In vitro susceptibilities of bloodstream isolates of Candida species to six antifungal agents: results from a population-based active surveillance programme, Barcelona, Spain, 2002-2003. J Antimicrob Chemother 55 (2005) 194-199
6. Dupont B. Nouveaux antifongiques: voriconazole et caspofungine. Arch Ped 10 Suppl 5 (2003) 592-598
7. Espinel-Ingroff A. In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12.052 fungal isolates: review of the literature. Rev Iberoam Micol 20 (2003) 121-136
8. Hospenthal D.R., Murray C.K., and Rinaldi M.G. The role of antifungal susceptibility testing in the therapy of candidiasis. Diag Microbiol Infect Dis 48 (2004) 153-160
9. Loeffler J., and Stevens D.A. Antifungal drug resistance. Clin Infect Dis 36 (2003) 31-41
10. Magiorakos A.P., and Hadley S. Impact of real-time fungal susceptibility on clinical practices. Curr Opin Infect Dis 17 (2004) 511-515
11. Mora-Duarte J., Betts R., Rotstein C., Colombo A.L., Thompson-Moya L., Smietana J., et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Eng J Med 347 (2002) 2020-2029
12. Muller F.M., Weig M., Peter J., and Walsh T.J. Azole cross-resistance to ketoconazole, fluconazole, itraconazole and voriconazole in clinical Candida albicans isolates from HIV-infected children with oropharyngeal candidosis. J Antimicrob Chemother 46 (2000) 338-340
13. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeasts; approved Standard. Second edition, document M27-A2. National Committee for Clinical Laboratory Standards, Wayne, Pa. 2002.
14. Ostrosky-Zeichner L., Rex J.H., Pappas P.G., Hamill R.J., Larsen R.A., Horowitz H.W., et al. Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. Antimicrob Agents Chemother 47 (2003) 3149-3154
15. Peman J., Canton E., Gobernado M., and The Spanish ECMM Working Group. Candidaemia Epidemiology and antifungal susceptibility of Candida species isolated from blood: results of a 2-year multicentre study in Spain. Eur J Clin Microbiol Infect Dis 24 (2005) 23-30
16. Pfaller M.A., Messer S.A., Boyken L., Rice C., Tendolkar S., Hollis R.J., et al. Caspofungin activity against clinical isolates of fluconazole-resistant Candida. J Clin Microbiol 41 (2003) 5729-5731
17. Pfaller M.A., Messer S.A., Boyken L., Rice C., Tendolkar S., Hollis R.J., et al. Further standardization of broth microdilution methodology for in vitro susceptibility testing of caspofungin against Candida species by use of an international collection of more than 3000 clinical isolates. J Clin Microbiol 42 (2004) 3117-3119
18. Pfaller M.A., Messer S.A., Hollis R.J., Jones R.N., and Diekema D.J. In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6970 clinical isolates of Candida spp. Antimicrob Agents Chemother 46 (2002) 1723-1727
19. Rodríguez-Tudela J.L., and Cuenca-Estrella M. A multicenter study on fungemia caused by yeasts in Spain (April-June 1997). A work group to study fungemia. Rev Clin Esp 199 (1999) 356-361
20. St-Germain G., Laverdiere M., Pelletier R., Bourgault A.M., Libman M., Lemieux C., et al. Prevalence and antifungal susceptibility of 442 Candida isolates from blood and other normally sterile sites: results of a 2-year (1996 to 1998) multicenter surveillance study in Quebec Canada. J Clin Microbiol 39 (2001) 949-953